Tumor levels of the mediators of ErbB2-driven anoikis resistance correlate with breast cancer relapse in patients receiving trastuzumab-based therapies-Reference-Cited by-同舟云学术

Tumor levels of the mediators of ErbB2-driven anoikis resistance correlate with breast cancer relapse in patients receiving trastuzumab-based therapies

Published:2021-03-16 Issue:3 Volume:187 Page:743-758
ISSN:0167-6806
Container-title:Breast Cancer Research and Treatment
language:en
Short-container-title:Breast Cancer Res Treat

Author:

Surette Alexi,Yoo Byong Hoon,Younis Tallal,Matheson Kara,Rameh Tarek,Snowdon Jaime,Bethune Gillian,Rosen Kirill V.^ORCID

Funder

Canadian Institutes of Health Research

Beatrice Hunter Cancer Research Institute

Publisher

Springer Science and Business Media LLC

Subject

Cancer Research,Oncology

Link

https://link.springer.com/content/pdf/10.1007/s10549-021-06164-0.pdf

Reference43 articles.

1. Bethune GC, van Zanten DV, MacIntosh RF, Rayson D, Younis T, Thompson K, Barnes PJ (2015) Impact of the 2013 American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 (HER2) testing of invasive breast carcinoma: a focus on tumours assessed as ‘equivocal’ for HER2 gene amplification by fluorescence in-situ hybridization. Histopathology 67:880–887. https://doi.org/10.1111/his.12723

2. Bartsch R, Wenzel C, Steger GG (2007) Trastuzumab in the management of early and advanced stage breast cancer. Biologics 1:19–31

3. Untch M, Fasching PA, Konecny GE, Hasmuller S, Lebeau A, Kreienberg R, Camara O, Muller V, du Bois A, Kuhn T et al (2011) Pathologic complete response after neoadjuvant chemotherapy plus trastuzumab predicts favorable survival in human epidermal growth factor receptor 2-overexpressing breast cancer: results from the TECHNO trial of the AGO and GBG study groups. J Clin Oncol 29:3351–3357. https://doi.org/10.1200/JCO.2010.31.4930

4. Untch M, Rezai M, Loibl S, Fasching PA, Huober J, Tesch H, Bauerfeind I, Hilfrich J, Eidtmann H, Gerber B et al (2010) Neoadjuvant treatment with trastuzumab in HER2-positive breast cancer: results from the GeparQuattro study. J Clin Oncol 28:2024–2031. https://doi.org/10.1200/JCO.2009.23.8451

5. Triulzi T, Bianchi GV, Tagliabue E (2016) Predictive biomarkers in the treatment of HER2-positive breast cancer: an ongoing challenge. Future Oncol 12:1413–1428. https://doi.org/10.2217/fon-2015-0025

Cited by 6 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Identification of anoikis-related subtypes and immune landscape in kidney renal clear cell carcinoma;Scientific Reports;2023-10-23

2. Anoikis resistance––protagonists of breast cancer cells survive and metastasize after ECM detachment;Cell Communication and Signaling;2023-08-03

3. Predicting the immune microenvironment and prognosis with a anoikis - related signature in breast cancer;Frontiers in Oncology;2023-07-04

4. Identification and experimental verification of an anoikis and immune related signature in prognosis for lung adenocarcinoma;Translational Cancer Research;2023-04

5. Identification and Validation of the Anoikis-Related Gene Signature as a Novel Prognostic Model for Cervical Squamous Cell Carcinoma, Endocervical Adenocarcinoma, and Revelation Immune Infiltration;Medicina;2023-02-13